Associated Press (01/13/12)
The FDA would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with industry released by the agency. Whereas most new drugs are reviewed in 10 months, the typical review time for a generic drug is 30 months. The FDA has a backlog of 2,500 generic drug applications awaiting review. The FDA proposes collecting $299 million in fees annually to hire additional generic drug reviewers. The proposal must be approved by Congress to become law.

Read the complete article